Telix Pharmaceuticals (NASDAQ:TLX) Given Outperform Rating at Wedbush

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating restated by Wedbush in a research note issued on Monday,Benzinga reports. They currently have a $22.00 target price on the stock. Wedbush’s price objective would suggest a potential upside of 85.34% from the stock’s current price.

Several other research analysts have also weighed in on TLX. Wall Street Zen raised Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Monday, April 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a research note on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $21.12.

Telix Pharmaceuticals Price Performance

Shares of NASDAQ:TLX opened at $11.87 on Monday. Telix Pharmaceuticals has a 1 year low of $6.28 and a 1 year high of $16.98. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The business has a fifty day simple moving average of $10.23 and a 200 day simple moving average of $8.84.

Insider Transactions at Telix Pharmaceuticals

In other Telix Pharmaceuticals news, CEO Christian Behrenbruch bought 33,435 shares of the stock in a transaction on Wednesday, April 29th. The shares were purchased at an average cost of $14.87 per share, with a total value of $497,178.45. Following the completion of the transaction, the chief executive officer directly owned 20,742,935 shares of the company’s stock, valued at $308,447,443.45. This represents a 0.16% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Institutional Trading of Telix Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers increased its holdings in shares of Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after acquiring an additional 1,392 shares during the last quarter. XTX Topco Ltd acquired a new stake in Telix Pharmaceuticals in the 4th quarter worth approximately $89,000. Bank of America Corp DE lifted its holdings in Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after purchasing an additional 8,423 shares during the last quarter. OLD Mission Capital LLC bought a new stake in Telix Pharmaceuticals during the fourth quarter worth approximately $111,000. Finally, XY Capital Ltd bought a new stake in Telix Pharmaceuticals during the first quarter worth approximately $120,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.